ArticleCureus2024
Prognostic and Molecular Characterization of Metastatic Transverse Colon Cancer: Insights From a Single-Center Retrospective Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetastatic transverse colon cancer (TCC) represents a unique subset of colorectal cancer with features of both right and left colon tumors due to its distinct embryologic origin. This study retrospectively analyzes the clinical, pathological, and molecular factors influencing survival outcomes in TCC patients treated at a single center.
methodsFor this study, we reviewed the files of 372 metastatic patients and analyzed the data of 71 patients with a diagnosis of TCC in detail. The remaining patients were patients with right or left colon tumors and we compared the overall survival (OS), molecular mutations (KRAS, NRAS, BRAF, MSI status), and clinicopathological features of our patients with transverse colon tumors with these patients.
resultsThe median OS for TCC patients was 19.7 months, with metastasectomy and Eastern Cooperative Oncology Group (ECOG) performance status emerging as significant prognostic factors. Molecular analyses revealed KRAS mutations in 49% and BRAF mutations in 13% of TCC cases, aligning TCC closer to right-sided tumors in certain molecular characteristics. However, histopathologic diversity, including mucinous histology in 20% of TCC cases, indicated a need to consider TCC as a distinct entity.
conclusionThese findings underscore the complex biological nature of TCC and the necessity for tailored therapeutic approaches, especially as survival rates remain suboptimal. Further multicenter, prospective studies are recommended to establish refined treatment strategies for TCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.